GPD1L
Basic information
Region (hg38): 3:32105689-32168709
Links
Phenotypes
GenCC
Source:
- Brugada syndrome 2 (Limited), mode of inheritance: Unknown
- Brugada syndrome 2 (Limited), mode of inheritance: AD
- Brugada syndrome 1 (Disputed Evidence), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Brugada syndrome 2 | AD | Cardiovascular; Pharmacogenomic | Surveillance with approximately yearly EKG and medical interventions, including daily quinidine for prevention (though treatment of asymptomatic individuals is controversial), ICD placement in individuals with previous cardiac arrest/syncope, and isoproterenol for electrical storms, may be beneficial; Certain agents should be avoided, including medications such as certain anesthetics, antidepressants, and antipsychotics, and care should be taken in the instance of high fever | Cardiovascular | 11839626; 17967977; 17967976 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GPD1L gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 88 | 94 | ||||
missense | 151 | 153 | ||||
nonsense | 2 | |||||
start loss | 1 | |||||
frameshift | 5 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 5 | |||||
splice region | 3 | 13 | 2 | 18 | ||
non coding | 42 | 31 | 75 | |||
Total | 0 | 0 | 169 | 133 | 35 |
Variants in GPD1L
This is a list of pathogenic ClinVar variants found in the GPD1L region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-32106298-G-A | Benign (Jul 05, 2018) | |||
3-32106347-G-A | Likely benign (Jun 14, 2018) | |||
3-32106421-G-A | Benign (Jun 19, 2018) | |||
3-32106479-CGGGCCTGGAGGCCGGCCG-C | Benign (Mar 21, 2019) | |||
3-32106485-T-G | Benign (Jun 19, 2018) | |||
3-32106580-G-A | Brugada syndrome | Uncertain significance (Jun 14, 2016) | ||
3-32106593-C-T | Benign (Mar 03, 2015) | |||
3-32106665-C-G | not specified | Likely benign (Dec 19, 2016) | ||
3-32106712-A-G | Brugada syndrome • Cardiovascular phenotype | Uncertain significance (Oct 25, 2021) | ||
3-32106716-C-T | Uncertain significance (Apr 06, 2023) | |||
3-32106718-GC-G | Uncertain significance (Aug 20, 2014) | |||
3-32106719-C-T | Cardiovascular phenotype | Uncertain significance (Apr 18, 2024) | ||
3-32106720-G-A | Brugada syndrome | Likely benign (Jan 17, 2024) | ||
3-32106722-C-A | Cardiovascular phenotype | Uncertain significance (Feb 22, 2023) | ||
3-32106722-C-T | Brugada syndrome • Cardiovascular phenotype | Uncertain significance (Feb 13, 2023) | ||
3-32106725-C-T | Brugada syndrome | Uncertain significance (Feb 25, 2020) | ||
3-32106726-C-T | Brugada syndrome | Likely benign (Feb 27, 2018) | ||
3-32106738-C-T | Brugada syndrome | Likely benign (Jan 28, 2022) | ||
3-32106749-C-T | Brugada syndrome | Uncertain significance (Sep 01, 2021) | ||
3-32106751-G-A | Brugada syndrome | Uncertain significance (May 07, 2019) | ||
3-32106752-G-A | Brugada syndrome | Uncertain significance (Jan 12, 2022) | ||
3-32106755-A-G | Brugada syndrome | Uncertain significance (Dec 13, 2023) | ||
3-32106759-G-A | Brugada syndrome • Cardiovascular phenotype | Uncertain significance (Mar 13, 2023) | ||
3-32106775-T-C | not specified | Uncertain significance (Feb 05, 2023) | ||
3-32106777-G-C | Brugada syndrome | Likely benign (Apr 11, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GPD1L | protein_coding | protein_coding | ENST00000282541 | 8 | 63025 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0382 | 0.956 | 125735 | 0 | 13 | 125748 | 0.0000517 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.08 | 157 | 200 | 0.786 | 0.0000114 | 2307 |
Missense in Polyphen | 55 | 77.775 | 0.70717 | 913 | ||
Synonymous | 0.0118 | 78 | 78.1 | 0.998 | 0.00000518 | 688 |
Loss of Function | 2.39 | 5 | 15.0 | 0.334 | 7.04e-7 | 184 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000248 | 0.000246 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000617 | 0.0000615 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000653 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Plays a role in regulating cardiac sodium current; decreased enzymatic activity with resulting increased levels of glycerol 3-phosphate activating the DPD1L-dependent SCN5A phosphorylation pathway, may ultimately lead to decreased sodium current; cardiac sodium current may also be reduced due to alterations of NAD(H) balance induced by DPD1L. {ECO:0000269|PubMed:19666841, ECO:0000269|PubMed:19745168}.;
- Pathway
- Glycerophospholipid metabolism - Homo sapiens (human);Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways;Metabolism of lipids;Metabolism;Glycerophospholipid biosynthesis;Phospholipid metabolism;Synthesis of PA
(Consensus)
Recessive Scores
- pRec
- 0.174
Intolerance Scores
- loftool
- 0.504
- rvis_EVS
- -0.49
- rvis_percentile_EVS
- 22.36
Haploinsufficiency Scores
- pHI
- 0.572
- hipred
- N
- hipred_score
- 0.276
- ghis
- 0.566
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.966
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gpd1l
- Phenotype
Gene ontology
- Biological process
- action potential;regulation of heart rate;carbohydrate metabolic process;phosphatidic acid biosynthetic process;positive regulation of sodium ion transport;NAD metabolic process;negative regulation of peptidyl-serine phosphorylation;glycerol-3-phosphate catabolic process;regulation of ventricular cardiac muscle cell membrane depolarization;ventricular cardiac muscle cell action potential;negative regulation of protein kinase C signaling;positive regulation of protein localization to cell surface;regulation of sodium ion transmembrane transporter activity
- Cellular component
- cytosol;plasma membrane;glycerol-3-phosphate dehydrogenase complex;extracellular exosome
- Molecular function
- glycerol-3-phosphate dehydrogenase [NAD+] activity;sodium channel regulator activity;protein homodimerization activity;ion channel binding;NAD binding